Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD1222 (Vaxzevria) in Immunocompromised Adults
NCT05057897Phase 4Terminated
- Sponsor
- AstraZeneca
- Start
- Jan 2022
- Primary completion
- Apr 2023
- Modality
- Viral Vector Vaccines
- Countries
- 2
01
Overview
A Phase 4 trial of ChAdOx1 nCoV-19 in coronavirus disease 2019 (COVID-19), sponsored by AstraZeneca. Started Jan 2022; status: terminated.
02
Drugs
ChAdOx1 nCoV-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05057897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05057897.